Achillion Pharmaceuticals Inc (NASDAQ:ACHN)

11.43
Data as of Oct 21
 +0.44 / +4.00%
Today’s Change
2.26
Today|||52-Week Range
13.80
+244.38%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.1B

Company Description

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative treatments for infectious diseases. The company is currently engaged in the development of antivirals for the treatment of chronic hepatitis C infection and resistant bacterial infections. Its products include ACH-3102, ACH-2684, Sovaprevir and ACH-3422. Achillion Pharmaceuticals was founded on August 17, 1998 and is headquartered in New Haven, CT.

Contact Information

Achillion Pharmaceuticals, Inc.
300 George Street
New Haven Connecticut 06511
P:(203) 624-7000
Investor Relations:
(203) 752-5510

Employees

Shareholders

Individual stakeholders37.10%
Mutual fund holders34.09%
Other institutional33.19%

Top Executives

Milind S. DeshpandePresident, Chief Executive Officer & Director
Mary Kay FentonCFO, Secretary, EVP & Investor Relations Contact
David ApelianChief Medical Officer & Executive Vice President
Joseph TruittChief Commercial Officer & Executive VP
Glenn SchulmanHead-Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.